Bolt Biotherapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
BOLT$6.43-1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $7,205 | $10,810 |
| Short-term investments | 40,118 | 91,379 |
| Restricted cash | 784 | — |
| Prepaid expenses and other current assets | 2,707 | 3,519 |
| Total current assets | 50,814 | 105,708 |
| Property and equipment, net | 3,139 | 4,957 |
| Operating lease right-of-use assets | 21,756 | 19,120 |
| Restricted cash, non-current | 981 | 1,765 |
| Long-term investments | 22,880 | 26,413 |
| Other assets | 62 | 1,821 |
| Total assets | $99,632 | $159,784 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $1,507 | $2,987 |
| Accrued expenses and other current liabilities | 9,083 | 12,486 |
| Deferred revenue | 3,015 | 2,201 |
| Operating lease liabilities | 2,251 | 2,782 |
| Total current liabilities | 15,856 | 20,456 |
| Operating lease liabilities, net of current portion | 22,958 | 17,437 |
| Deferred revenue, non-current | 3,620 | 9,107 |
| Other long-term liabilities | — | 43 |
| Total liabilities | 42,434 | 47,043 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 38,339,697 and 38,114,606 shares issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Additional paid-in capital | 484,504 | 476,989 |
| Accumulated other comprehensive gain | 97 | 37 |
| Accumulated deficit | (427,403) | (364,285) |
| Total stockholders' equity | 57,198 | 112,741 |
| Total liabilities and stockholders' equity | $99,632 | $159,784 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.